CLYTE develops AI-on-edge tools and services designed to enhance the ease, efficiency, and standardization of basic research in biomedical and life sciences. The company focuses on streamlining redundant laboratory procedures and automating complex data analysis using proprietary AI/ML models trained on standardized datasets. Their offerings range from open-access AI tools to custom solutions aimed at minimizing confounding variability in research workflows.
Funding
Funding not disclosed
Founders
Product
Problem
Basic research in biomedical and life sciences often involves time-consuming and redundant procedures that can lead to variability and non-reproducible data. Many preclinical research tasks lack efficient, automated solutions, hindering the pace of discovery and standardization.
Solution
CLYTE Technologies develops and provides innovative biotech tools and services designed to enhance the ease, efficiency, and standardization of basic research procedures. Their products tackle inefficiencies in biomedical and life-science research by automating data analysis and streamlining lab processes. CLYTE's solutions minimize confounding variability, leading to higher quality and more standardized research data. The company also offers custom solutions tailored to specific research needs, including the First-Client initiative for beta testing pre-market innovations.
Target Audience
CLYTE's primary customers are researchers and students in biomedical and life sciences seeking to improve the efficiency, reproducibility, and standardization of their experiments.
Features
- Automated data analysis tools integrated into products and available as online services
- Specialization in transforming time-consuming procedures into faster, automated tasks
- CellCut: A tool for applying uniform and unique scratches for 2D scratch assays, eliminating user application variability
- Cadmus: A cell culture monitoring tool for enhanced cell culture procedures
- Standard Operating Procedures (SOPs) aligned with open science efforts
- First-Client Initiative: Partnership program for testing pre-market biotech innovations